Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHetty E. CarrawayBRBenjamin RollesAHAmyah Harris

Discussion

Loading...

Member takes

Overview

Analysis reveals significant cCR rate improvement with venetoclax in HR-MDS, indicating TP53 mutations influence outcomes.

Key Points

  • Higher cCR rates were observed in patients treated with venetoclax compared to those treated with hypomethylating agents alone.
  • Patients receiving venetoclax showed a cCR of 48.8% versus 27.7% in hypomethylating agents, highlighting treatment efficacy.
  • The study utilized Kaplan-Meier methods and log-rank tests to analyze survival outcomes among MDS patients.
  • Findings suggest that TP53 mutation status significantly impacts treatment responses and overall survival.

Cite This Study

Carraway et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd81https://doi.org/10.1182/blood-2025-606
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes2025
  2. 2The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes2025
  3. 3Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party2025
  4. 4Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  5. 5IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025